Medical Communications
AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial
September 11, 2023 Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial
Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate
September 7, 2023 Medical Communications Infections and infestations, Pfizer, Vaccine, Valneva, clinical trial, lyme disease
AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment
September 4, 2023 Medical Communications AstraZeneca, CLL, China, Oncology, SLL
Novo Nordisk launches Wegovy in the UK
September 4, 2023 Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss
FDA approves new ADHD and BED generics
September 1, 2023 Medical Communications BED, FDA, Pharmacy, generic medicines
First patient dosed in phase 1 study for chronic hepatitis B treatment
August 31, 2023 Medical Communications Chronic Diseases, ISA Pharmaceuticals, ISA104, clinical trial, hepatitis B
FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS
August 25, 2023 Medical Communications FDA, MS, Neurology, Sandoz
Tarsus Pharmaceuticals’ Xdemvy approved by FDA for treatment of Demodex blepharitis
August 25, 2023 Medical Communications Demodex blepharitis, FDA, Opthalmology, Tarsus Pharmaceuticals, eyedrops
Japan approves AstraZeneca’s Soliris for paediatric patients with gMG
August 24, 2023 Medical Communications AstraZeneca, MHLW, Musculo-skeletal disorder, gMG, paediatric, soliris
FDA grants ODD to NXC-201 as multiple myeloma treatment
August 24, 2023 Medical Communications FDA, Nexcella, ODD, Oncology, multiple myeloma
Daiichi Sankyo’s Enhertu approved in Japan as treatment for metastatic NSCLC
August 23, 2023 Medical Communications Daiichi Sankyo, Enhertu, Japan's MHLW, NSCLC, Oncology, trastuzumab deruxtecan
AstraZeneca’s Forxiga approved in China for chronic heart failure treatment
August 18, 2023 Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure
Iveric Bio’s marketing authorisation application for avacincaptad pegol accepted by EMA
August 18, 2023 Medical Communications CHMP, EMA, Iveric Bio, MAA, Opthalmology
Amicus Therapeutics’ Pompe disease treatment approved for use in UK
August 17, 2023 Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases
FDA approved Ipsen’s Sohonos capsules for treatment of fibrodysplasia ossificans progressiva
August 17, 2023 Medical Communications FDA, FOP, Musculo-skeletal disorder, Sohonos, ipsen
Latest content
